Evotec AG, through its U.S. subsidiary, has entered a multi-year compound management agreement with the Medicines for Malaria Venture (MMV) to support its Malaria and Pathogen Box initiatives aimed at transforming drug discovery efforts for malaria and other neglected diseases. Financial details were not disclosed.
Evotec will leverage its compound management services to support MMV's efforts to establish, maintain and distribute research tools to the global malaria research community. Evotec will deliver an industrialized, comprehensive compound management infrastructure to support all aspects of the collaboration.
Dr. Mario Polywka, chief operating officer of Evotec, said, "We are pleased to partner with the Medicines for Malaria Venture and to support these important initiatives. We are confident that our team will provide high-quality services as required to support MMV, their investigators and ultimately patients."
Dr. Tim Wells, chief scientific officer of MMV, said, "Researchers are starved of access to promising molecules due to financial and technical barriers. MMV's Malaria and Pathogen Box initiatives aim to remove these barriers and suppliers like Evotec are critical to their success. We look forward to jointly ensuring robust compounds enter the R&D process and the best ones are developed into effective new medicines for vulnerable populations."